Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per Oncotype, but met NATALEE inclusion criteria?

Yes, I would recommend adjuvant ribociclib.

I would consider it, but, unfortunately, we don't have data on the benefit (or lack thereof) of adjuvant CDK 4/6 inhibitor therapy (either ribociclib or abemaciclib) correlated with Oncotype score, but I would keep in mind that Oncotype is prognostic as well as predictive, so I am less likely to rec...